<DOC>
	<DOC>NCT01968044</DOC>
	<brief_summary>Therapuetic options are limited for Type 2 Diabetes Mellitus (T2DM) pateints with renal impairment. This clinical study is to asses safety and efficacy of the DPP-4 inhibitor gemigliptin in patients with type 2 DM and moderate or severe renal impairment for long-term peirod (52 weeks).</brief_summary>
	<brief_title>A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patients with Type 2 Diabetes Mellitus Patients with moderate or severe renal insufficiency All patients give written informed consent Has type 1 diabetes mellitus or a history of ketoacidosis Is on dialysis or is likely to need dialysis during the study Has active liver disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>renal impairment</keyword>
</DOC>